REmote SUpervision to Decrease HospitaLization RaTe. Unified and integrated platform for data collected from devices manufactured by different companies: Design and rationale of the RESULT study
Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński, Mateusz Tajstra, Adam Sokal, Arkadiusz Gwóźdź, Marcin Wilczek, Adam Gacek, Konrad Wojciechowski, Elżbieta Gadula-Gacek, Elżbieta Adamowicz-Czoch, Katarzyna Chłosta-Niepiekło, Krzysztof Milewski, Piotr Rozentryt, Zbigniew Kalarus, Mariusz Gąsior, Lech Poloński
Abstract
The number of patients with heart failure implantable cardiac electronic devices (CIEDs) is growing. Hospitalization rate in this group is very high and generates enormous costs. To avoid the need for hospital treatment, optimized monitoring and follow-up is crucial. Remote monitoring (RM) has been widely put into practice in the management of CIEDs but it may be difficult due to the presence of differences in systems provided by device manufacturers and loss of gathered data in case of device reimplantation. Additionally, conclusions derived from studies about usefulness of RM in clinical practice apply to devices coming only from a single company. An integrated monitoring platform allows for more comprehensive data analysis and interpretation. Therefore, the primary objective of Remote Supervision to Decrease Hospitalization Rate (RESULT) study is to evaluate the impact of RM on the clinical status of patients with ICDs or CRT-Ds using an integrated platform. Six hundred consecutive patients with ICDs or CRT-Ds implanted will be prospectively randomized to either a traditional or RM-based follow-up model. The primary clinical endpoint will be a composite of all-cause mortality or hospitalization for cardiovascular reasons within 12 months after randomization. The primary technical endpoint will be to construct and evaluate a unified and integrated platform for the data collected from RM devices manufactured by different companies. This manuscript describes the design and methodology of the prospective, randomized trial designed to determine whether remote monitoring using an integrated platform for different companies is safe, feasible, and efficacious (ClinicalTrials.gov Identifier: NCT02409225).
Keywords: RESULT study; heart failure; integrated platform; remote monitoring.
Conflict of interest statement
None declared.
© 2016 Wiley Periodicals, Inc.
Figures



Source: PubMed
Nadchodzące badania kliniczne
-
Aperta Biosciences, LLCJeszcze nie rekrutacja
-
Hospices Civils de LyonJeszcze nie rekrutacjaNiemożność utrzymania moczu | Pęcherz neurogenny | Odprowadzenie moczu | Nowotwór miednicy mniejszej | Rak pęcherza moczowegoFrancja
-
Second Affiliated Hospital, Zhejiang University...RekrutacyjnyNormalny słuch | Ekspozycja na hałas | Preferred Loudness LevelChiny
-
Qilu Pharmaceutical Co., Ltd.Jeszcze nie rekrutacjaRak jasnokomórkowy nerki | Rak jajnika | Inne zaawansowane guzy liteChiny
-
University Hospital, AntwerpJeszcze nie rekrutacjaMartwicze zapalenie jelit u noworodków | Późna posocznica noworodkówBelgia, Holandia
-
VA Office of Research and DevelopmentJeszcze nie rekrutacjaNiedrobnokomórkowy rak płuc z przerzutami | Cancer-Associated Weight Loss | Elevated Inflammatory MarkersStany Zjednoczone
-
ENTire Medical Ltd.Jeszcze nie rekrutacjaHipertrofia | Wycięcie migdałków | Górna niedrożność dróg oddechowych | Operacja adenotomiiStany Zjednoczone
-
AbbVieJeszcze nie rekrutacjaUmiarkowana do ciężkiej łuszczycy
-
Institute of Hematology & Blood Diseases Hospital...RekrutacyjnyAnemia aplastyczna | Hematopoeza klonalna | Terapia immunosupresyjnaChiny
-
Ahmed Nasser Ali MabkhoutRekrutacyjnyTorbiele szczęki | Alveolar Bone DefectsJemen
-
University of CoimbraJeszcze nie rekrutacja
-
AbbVieJeszcze nie rekrutacja